P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy

Douguet L, Janho dit Hreich S, Benzaquen J, Seguin L, Juhel T, Dezitter X, Duranton C, Ryffel B, Kanellopoulos J, Delarasse C, Renault N, Furman C, Homerin G, Féral C, Cherfils-Vicini J, Millet R, Adriouch S, Ghinet A, Hofman P, Vouret-Craviari V (2021) A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat Commun 12(1):653. https://doi.org/10.1038/s41467-021-20912-2

Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272(5262):735–738. https://doi.org/10.1126/science.272.5262.735

Di Virgilio F, Bronte V, Collavo D, Zanovello P (1989) Responses of mouse lymphocytes to extracellular adenosine 5'-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol 143(6):1955–1960

Wiley JS, Dubyak GR (1989) Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes. Blood 73(5):1316–1323

Spranzi E, Djeu JY, Hoffman SL, Epling-Burnette PK, Blanchard DK (1993) Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor. Blood 82(5):1578–1585

Orioli E, De Marchi E, Giuliani AL, Adinolfi E (2017) P2X7 receptor orchestrates multiple signalling pathways triggering inflammation, autophagy and metabolic/trophic responses. Curr Med Chem 24(21):2261–2275. https://doi.org/10.2174/0929867324666170303161659

Di Virgilio F, Schmalzing G, Markwardt F (2018) The elusive P2X7 macropore. Trends Cell Biol 28(5):392–404. https://doi.org/10.1016/j.tcb.2018.01.005

Solini A, Chiozzi P, Morelli A, Fellin R, Di Virgilio F (1999) Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J Cell Sci 112(Pt 3):297–305

Ferrari D, Wesselborg S, Bauer MK, Schulze-Osthoff K (1997) Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol 139(7):1635–1643. https://doi.org/10.1083/jcb.139.7.1635

Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E, Rubini M, Di Virgilio F (1996) An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 87(2):682–690

Di Virgilio F (2021) P2X7 is a cytotoxic receptor....maybe not: implications for cancer. Purinergic Signal 17(1):55–61. https://doi.org/10.1007/s11302-020-09735-w

Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, Di Virgilio F (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72(12):2957–2969. https://doi.org/10.1158/0008-5472.CAN-11-1947

Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, López-Picazo JM, Sanmamed MF, Melero I (2021) Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-1312

Gelin CF, Bhattacharia A, Letavic MA (2020) P2X7 receptor antagonists for the treatment of systemic inflammatory disorders. Prog Med Chem 59:63–99. https://doi.org/10.1016/bs.pmch.2019.11.002

Shabbir M, Thompson C, Jarmulowiczc M, Mikhailidis D, Burnstock G (2008) Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU Int 102(1):108–112. https://doi.org/10.1111/j.1464-410X.2008.07578.x

Lara R, Adinolfi E, Harwood CA, Philpott M, Barden JA, Di Virgilio F, McNulty S (2020) P2X7 in cancer: from molecular mechanisms to therapeutics. Front Pharmacol 11:793. https://doi.org/10.3389/fphar.2020.00793

Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D, Pinton P, Jorgensen NR, Abelli L, Emionite L, Raffaghello L, Pistoia V, Di Virgilio F (2015) Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res 75(4):635–644. https://doi.org/10.1158/0008-5472.CAN-14-1259

Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47(1):15–31. https://doi.org/10.1016/j.immuni.2017.06.020

De Marchi E, Orioli E, Pegoraro A, Sangalletti S, Portararo P, Curti A, Colombo MP, Di Virgilio F, Adinolfi E (2019) The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38(19):3636–3650. https://doi.org/10.1038/s41388-019-0684-y

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3(7):e2599. https://doi.org/10.1371/journal.pone.0002599

Kamata-Sakurai M, Narita Y, Hori Y, Nemoto T, Uchikawa R, Honda M, Hironiwa N, Taniguchi K, Shida-Kawazoe M, Metsugi S, Miyazaki T, Wada NA, Ohte Y, Shimizu S, Mikami H, Tachibana T, Ono N, Adachi K, Sakiyama T, Matsushita T, Kadono S, Komatsu SI, Sakamoto A, Horikawa S, Hirako A, Hamada K, Naoi S, Savory N, Satoh Y, Sato M, Noguchi Y, Shinozuka J, Kuroi H, Ito A, Wakabayashi T, Kamimura M, Isomura F, Tomii Y, Sawada N, Kato A, Ueda O, Nakanishi Y, Endo M, Jishage KI, Kawabe Y, Kitazawa T, Igawa T (2020) Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation. Cancer Discov 11:158–175. https://doi.org/10.1158/2159-8290.CD-20-0328

Mimoto F, Tatsumi K, Shimizu S, Kadono S, Haraya K, Nagayasu M, Suzuki Y, Fujii E, Kamimura M, Hayasaka A, Kawauchi H, Ohara K, Matsushita M, Baba T, Susumu H, Sakashita T, Muraoka T, Aso K, Katada H, Tanaka E, Nakagawa K, Hasegawa M, Ayabe M, Yamamoto T, Tanba S, Ishiguro T, Kamikawa T, Nambu T, Kibayashi T, Azuma Y, Tomii Y, Kato A, Ozeki K, Murao N, Endo M, Kikuta J, Kamata-Sakurai M, Ishii M, Hattori K, Igawa T (2020) Exploitation of elevated extracellular ATP to specifically direct antibody to tumor microenvironment. Cell Rep 33(12):108542. https://doi.org/10.1016/j.celrep.2020.108542

Illes P, Müller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F (2021) Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol 178(3):489–514. https://doi.org/10.1111/bph.15299

Di Virgilio F, Giuliani AL, Vultaggio-Poma V, Falzoni S, Sarti AC (2018) Non-nucleotide agonists triggering P2X7 receptor activation and pore formation. Front Pharmacol 9:39. https://doi.org/10.3389/fphar.2018.00039

Stokes L, Bidula S, Bibič L, Allum E (2020) To inhibit or enhance? Is there a benefit to positive allosteric modulation of P2X receptors? Front Pharmacol 11:627. https://doi.org/10.3389/fphar.2020.00627